223 related articles for article (PubMed ID: 31663136)
1. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Clin Endocrinol (Oxf); 2020 Jan; 92(1):71-76. PubMed ID: 31663136
[TBL] [Abstract][Full Text] [Related]
2. Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.
Ahn J; Song E; Oh HS; Song DE; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Jun; 29(6):824-829. PubMed ID: 30864902
[No Abstract] [Full Text] [Related]
3. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
Cheng L; Fu H; Jin Y; Sa R; Chen L
Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.
Ha Y; Mohamed Ali MA; Petersen MM; Harmsen WS; Therneau TM; Lee HC; Ryoo BY; Bampoh S; Valles KA; Mady M; Missula VR; Prasai K; Roberts LR; Kim KM
Hepatol Int; 2020 Sep; 14(5):776-787. PubMed ID: 32740886
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Kuwahara C
Cancer Diagn Progn; 2021; 1(5):491-498. PubMed ID: 35403154
[TBL] [Abstract][Full Text] [Related]
9. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.
Lee SF; Ng TY; Spika D
BMC Cancer; 2019 Apr; 19(1):338. PubMed ID: 30971203
[TBL] [Abstract][Full Text] [Related]
11. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
12. Prognostic Significance of Absolute Lymphocyte Count, Absolute Monocyte Count, and Absolute Lymphocyte Count to Absolute Monocyte Count Ratio in Follicular Non-Hodgkin Lymphoma.
Mohsen A; Taalab M; Abousamra N; Mabed M
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e606-e615. PubMed ID: 32303487
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of lymphocyte-to-monocyte ratio in angioimmunoblastic T cell lymphoma].
Niu JY; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Wu JZ; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):265-270. PubMed ID: 29779318
[No Abstract] [Full Text] [Related]
14. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
15. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.
Lin ZX; Ruan DY; Li Y; Wu DH; Ma XK; Chen J; Chen ZH; Li X; Wang TT; Lin Q; Wen JY; Wu XY
World J Gastroenterol; 2015 Oct; 21(38):10898-906. PubMed ID: 26478681
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Low Lymphocyte-to-Monocyte Ratio Predicts Poor Clinical Outcomes for Patients with Urothelial Carcinoma of the Upper Urinary Tract.
Zhang XK; Yang P; Zhang ZL; Hu WM; Cao Y
Urol J; 2018 Nov; 15(6):348-354. PubMed ID: 30033515
[TBL] [Abstract][Full Text] [Related]
19. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
